These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31481585)

  • 1. Nuclear Medicine and Wall Street: An Evolving Relationship.
    Sherman M; Levine R
    J Nucl Med; 2019 Sep; 60(Suppl 2):20S-24S. PubMed ID: 31481585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economics of New Molecular Targeted Personalized Radiopharmaceuticals.
    Cutler CS
    Semin Nucl Med; 2019 Sep; 49(5):450-457. PubMed ID: 31470937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceutical therapy.
    Parman CC
    J Oncol Manag; 2002; 11(4):6-7. PubMed ID: 12182287
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of nuclear medicine.
    Ell PJ; Hoejgaard L; Becker W
    Lancet; 2002 Feb; 359(9306):629-30. PubMed ID: 11867148
    [No Abstract]   [Full Text] [Related]  

  • 5. Current applications and perspectives of diagnostic nuclear medicine in oncology. Task Group of Oncology.
    Bombardieri E; Carrio I; Gonzalez P; Serafini A; Turner JH; Virgolini I; Maffioli L
    Int J Oncol; 1999 May; 14(5):877-90. PubMed ID: 10200337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities.
    Graves SA; Bageac A; Crowley JR; Merlino DAM
    J Nucl Med; 2021 Dec; 62(Suppl 3):48S-59S. PubMed ID: 34857622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future of nuclear medicine, part 2: assessment of the U.S. diagnostic radio-pharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Mar; 39(3):20N, 22N-25N. PubMed ID: 9529277
    [No Abstract]   [Full Text] [Related]  

  • 8. Future of nuclear medicine, part 3: assessment of the U.S. therapeutic radiopharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Jul; 39(7):14N, 17N-18N, 20N-22N, 25N, 27N. PubMed ID: 9669377
    [No Abstract]   [Full Text] [Related]  

  • 9. CPT code recommendations for nuclear medicine therapy.
    McKusick KA; Wilson M
    J Nucl Med; 2002 Jul; 43(7):27N-28N. PubMed ID: 12109487
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
    Scott AM; Zeglis BM; Lapi SE; Scott PJH; Windhorst AD; Abdel-Wahab M; Giammarile F; Piaez D; Jalilian A; Knoll P; Korde A; Vichare S; Ayati N; Lee ST; Lyashchenko SK; Zhang J; Urbain JL; Lewis JS
    Lancet Oncol; 2024 Jun; 25(6):e250-e259. PubMed ID: 38821099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shaping our future.
    Chiti A
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1371-2. PubMed ID: 22820651
    [No Abstract]   [Full Text] [Related]  

  • 12. Nuclear imaging in cancer theranostics.
    Del Vecchio S; Zannetti A; Fonti R; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):152-63. PubMed ID: 17420716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy and regulatory news from SNM, Capitol Hill, and beyond.
    Cannon H
    J Nucl Med; 2007 Jul; 48(7):34N. PubMed ID: 17607036
    [No Abstract]   [Full Text] [Related]  

  • 14. [Imaging in oncology and international rules for evaluation: the nuclear medicine].
    Bourre JC; Vuillez JP
    Bull Cancer; 2009 Nov; 96(11):1127-37. PubMed ID: 19854694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of in vivo imaging of the central nervous system for developing novel drugs.
    Rueger MA; Kracht LW; Hilker R; Thiel A; Sobesky J; Winkeler A; Thomas AV; Heneka MT; Graf R; Herholz K; Heiss WD; Jacobs AH
    Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):164-81. PubMed ID: 17420717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.
    Turner JH
    Cancer Biother Radiopharm; 2019 Apr; 34(3):135-140. PubMed ID: 30973278
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges for nuclear medicine in the 1990s.
    Ell PJ
    Nucl Med Commun; 1992 Feb; 13(2):65-75. PubMed ID: 1436900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public affairs update. NM APC Task Force and proposed HOPPS changes.
    J Nucl Med; 2001 Nov; 42(11):16N, 21N. PubMed ID: 11710336
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of commercial nuclear pharmacy in the future practice of nuclear medicine.
    Callahan RJ
    Semin Nucl Med; 1996 Apr; 26(2):85-90. PubMed ID: 8723502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of radiopharmaceuticals in the hospital].
    Fotopoulos A
    Hell J Nucl Med; 2005; 8(1):29. PubMed ID: 15886749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.